stoxline Quote Chart Rank Option Currency Glossary
  
Gyre Therapeutics, Inc. (GYRE)
12.64  0.03 (0.24%)    07-12 12:21
Open: 12.74
High: 13.49
Volume: 24,127
  
Pre. Close: 12.61
Low: 12.64
Market Cap: 1,081(M)
Technical analysis
2024-07-12 12:20:25 PM
Short term     
Mid term     
Targets 6-month :  15.75 1-year :  18.4
Resists First :  13.48 Second :  15.75
Pivot price 11.51
Supports First :  10.65 Second :  8.89
MAs MA(5) :  12.46 MA(20) :  11.39
MA(100) :  14.99 MA(250) :  13.36
MACD MACD :  0.1 Signal :  -0.2
%K %D K(14,3) :  87.1 D(3) :  86.5
RSI RSI(14): 58.9
52-week High :  30.39 Low :  4.8
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ GYRE ] has closed below upper band by 18.6%. Bollinger Bands are 21.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 12.69 - 12.75 12.75 - 12.81
Low: 11.88 - 11.95 11.95 - 12.01
Close: 12.5 - 12.61 12.61 - 12.71
Company Description

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Headline News

Mon, 08 Jul 2024
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.3% - MarketBeat

Sun, 07 Jul 2024
Gyre Therapeutics (NASDAQ:GYRE) Shares Up 3.7% - Defense World

Fri, 05 Jul 2024
A. O. Smith sets quarterly dividend at 32 cents per share By Investing.com - Investing.com

Fri, 05 Jul 2024
Gyre Therapeutics Seeks Compliance Amid Board Reshuffle - TipRanks

Thu, 04 Jul 2024
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Down 7.0% in June - Defense World

Tue, 02 Jul 2024
Gyre Wins China Approval for Tablet to Treat Thrombocytopenia - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 86 (M)
Shares Float 16 (M)
Held by Insiders 81.7 (%)
Held by Institutions 0.9 (%)
Shares Short 189 (K)
Shares Short P.Month 170 (K)
Stock Financials
EPS -1.03
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.66
Profit Margin -75.8 %
Operating Margin 29.7 %
Return on Assets (ttm) 11 %
Return on Equity (ttm) -99.1 %
Qtrly Rev. Growth 9 %
Gross Profit (p.s.) 0
Sales Per Share 1.35
EBITDA (p.s.) 0.25
Qtrly Earnings Growth 201.5 %
Operating Cash Flow 18 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -12.54
PEG Ratio 0
Price to Book value 19.56
Price to Sales 9.54
Price to Cash Flow 60.12
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android